Clinical Trial

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke

Study acronym: KREATE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is a multicentre, randomized, blinded-endpoint trial that aims to evaluate the efficacy and safety of human urinary kallidinogenase combined with reteplase intravenous thrombolysis in the treatment of acute ischemic stroke
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-16.
Trial Details
NCT Number NCT07483281
Lead Sponsor China-Japan Union Hospital
Conditions Acute Ischemic Stroke
Enrollment 220 participants
Start Date 2026-05-01
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-03-30